Compare VanEck Uranium & Nuclear ETF (NLR) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Uranium & Nuclear ETF vs Nuvation Bio Inc. Class A Common Stock — how do they compare? VanEck Uranium & Nuclear ETF trades at $104.2 (market cap $3.51B), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.74B). The key difference: VanEck Uranium & Nuclear ETF is far larger — about 2× Nuvation Bio Inc. Class A Common Stock's market cap, and Nuvation Bio Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Uranium & Nuclear ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Uranium & Nuclear ETF for 7 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| NLR | NUVB | |
|---|---|---|
Market Cap | $3.51B | $1.74B |
Volume | 414,516 | 9,289,619 |
Sector | Sector/Thematic | Health |
52-Week High | $164.37 | $9.54 |
52-Week Low | $102.38 | $3.41 |
Typical Hold Time | 7 Days | 0 Days |
Enterprise Value | — | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About VanEck Uranium & Nuclear ETF
VanEck Uranium and Nuclear ETF seeks exposure to companies involved in uranium mining and the nuclear power industry. Its holdings may include miners, utilities, reactor-related companies, and nuclear equipment or service providers.
Read more on NLR →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
